Proposal For HL Company’s Stations Plasma Stations Project

With the growing demands for biological and health drug products of the world, and thegreat improvement of the production efficiency and the scale of production brought by therapid development biological technology, China’s biological pharmaceutical industry issustainably developing at an unprecedented speed. The blood products industry will maintaina rapid and stable growth in the next5-10years.Blood products are developed on the basis of clinical transfusion, which solve theproblem that whole blood is not easy to transport, its dosage is large and validity is short.Blood products are mainly used to cure tumor, liver disease, diabetes and immunologic(al)disease,etc. They also can be used in passive immunity, infectious diseases treatment,hemophilia treatment, surgery hemostasia and medical first aid. For the treatment andprevention of many serious diseases, the effect of blood products is irreplaceable, which a partof our country’s strategic sources.On one hand, with the growth of population, incidence of malignant disease andeconomy, the marketing demand for blood products maintains an annual increase more than15%. On the other hand, no more blood Products Company is approved to set since2001andthe import is also be limited. All these provide a relatively steady industry competitionenvironment. After the restructuring of solid plasma stations, we believe that the industrychain will be more unobstructed, which will be good for the long-term development of theindustry.The company was founded in1993, and was a designated production company approvedby national recognition. The company has been recognized for a national high and new techenterprise in2010. After sever years’efforts, this compay has had the industry leading edge inproduct lines and structures, development of plasma sources, technology and quality control,research and development ability and management. For the industrial development and thestrategic plan, this company needs to increase investment and enlarge market share.This article tries to provide detailed reference datas and the materials for investorsdecisions by analysising biological pharmaceutical industry and HL company. It can be usedas a case for investing analysis of biological pharmaceutical industry as well. At the sametime, it will provide a detailed industry analysis and management plan for the enterpriseswhich are willing to enter the industy...